Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. ihear

iHEAR SIGNED

Gene therapy of inherited and acquired hearing loss

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iHEAR project word cloud

Explore the words cloud of the iHEAR project. It provides you a very rough idea of what is the project "iHEAR" about.

efficiency    vector    ipsc    hc    transduction    incl    genes    people    impaired    caused    social    viral    otic    samples    causative    inner    perform    promoters    whom    lentiviral    patients    precision    congenital    explored    mutations    receptor    vivo    appropriate    mouse    patient    safety    neurons    experiments    hair    financial    models    protective    opportunity    corrective    once    world    cell    ganglion    spiral    acquired    medicine    constructs    primary    collection    configurations    mirnas    inherited    burden    proper    ear    vectors    correct    performing    marker    transgene    therapeutic    murine    million    stem    human    substantial    translatability    inducible    proof    strategies    aav    360    toolbox    genome    employed    gene    clinically    sgn    transfer    cells    alterations    wp2    lines    generate    editing    demonstrated    hearing    wp1    therapy    expression    tools    monogenetic    optimized    pluripotent    vitro    fluorescent    600    efficient    treatment    adeno    wp3    translatable    protect    model    proteins    designs    children    treat   

Project "iHEAR" data sheet

The following table provides information about the project.

Coordinator		 MEDIZINISCHE HOCHSCHULE HANNOVER 

Organization address
address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625
website: www.mh-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Total cost 1˙999˙500 €
 EC max contribution 1˙999˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-COG
 Funding Scheme ERC-COG
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2024-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙999˙500.00

Map

 Project objective

To address the substantial financial and social burden caused by hearing loss in 360 million people world-wide, I aim to improve hearing via gene therapy to correct inherited and protect from acquired hearing loss. In vitro experiments will establish the best vector configurations for transfer of therapeutic genes and miRNAs into inner ear hair cells (HC) and spiral ganglion neurons (SGN). The efficiency of the best-performing vector designs will then be explored in vivo using fluorescent marker proteins. Cell-type specific and inducible promoters as well as receptor-targeted vectors will be employed as a safety measure and to ensure transgene expression in HC and SGN target cells. Once efficient transduction of appropriate target cells and proper expression of therapeutic proteins are demonstrated, I will perform proof-of-concept studies in hearing loss models, incl. established mouse models, to correct (WP1) or protect (WP2) from impaired hearing. To ensure translatability of these findings, I will generate human induced pluripotent stem cells (iPSC) from patients with hearing loss (WP3), so that I can test optimized constructs in human otic cells. Moreover, I have access to a collection of well-characterized samples from over 600 hearing loss patients, including children with congenital hearing loss in whom many novel monogenetic alterations were identified. These resources provide the unique opportunity to generate a novel toolbox for the treatment of hearing loss. In addition to lentiviral and adeno-associated viral (AAV) vector delivery of corrective or protective genes to treat hearing loss, I will apply state-of-the-art genome editing tools to model and correct mutations causative for hearing loss in cell lines, primary cells from murine models, human patients and patient-derived iPSC. This work will contribute to development of clinically translatable approaches for precision medicine strategies to improve hearing loss treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IHEAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IHEAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More